Harianjogja.com, JAKARTA — The Sinopharm vaccine is part of the Mutual Cooperation Vaccine scheme. Sinopharm vaccine is a vaccine made in China and has been tested in several countries.
The Sinopharm vaccine has been listed by WHO and received EUA in China, United Arab Emirates, Bahrain, Egypt and Jordan, and now also in Indonesia.
Professor of the Faculty of Pharmacy UGM, Prof. Zullies Ikawati, explained that the Sinopharm vaccine uses the same platform as the Sinovac vaccine, namely an inactivated virus.
“In clinical trials in the United Arab Emirates, the efficacy of the Sinopharm vaccine reached 78 percent, and this vaccine can be used in the population aged 18 years and over to the elderly,” he said in an official statement received. Business, Monday (21/6/2021).
Because it has the same platform as the Sinovac vaccine, the side effect profile is also similar, where the frequency of side effects is 0.01 percent or categorized as very rare.
According to Prof. Zullies, the side effects encountered in clinical trials were mild local side effects, such as pain or redness at the injection site, and systemic side effects such as headache, muscle aches, fatigue, diarrhea and coughing.
These side effects improve quickly and generally do not require treatment. The public is asked not to worry about the side effects of vaccines, both AstraZeneca and Sinopharm vaccines.
In general, from the results of the evaluation of clinical trials that have involved thousands of people in various countries, the benefits of vaccines far outweigh the risks of side effects.
Post-Immunization Adverse Events (AEFI) are generally mild to moderate and individual, and the presence of AEFI also indicates that the vaccine is working.
However, if there is an AEFI that is felt to be severe, it must be reported immediately to the contact who has been given. That way, the incident can be treated immediately.
“In addition to being handled, AEFI will also be evaluated by the AEFI Committee regarding its causal relationship with vaccines so that it can become valuable data in the vaccination program,” he concluded.
Source: JIBI/Bisnis.com
– .
